GPR84 and colorectal carcinoma: Although GPR84 is currently considered an orphan receptor, the identification of more potent natural agonists, such as bacteria-derived medium-chain fatty acids, might be of great interest with regard to novel bacteria- or metabolite-based CRC therapeutic approaches.